Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.61 |
| ▸ | CA1 | P00915 | 8/20 | 0.61 |
| ▸ | CA2 | P00918 | 8/20 | 0.61 |
| ▸ | CA9 | Q16790 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10773830 | 0.90 | CA9 (0.65) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL6291291 | 0.81 | ALDH1A1 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10738787 | 0.81 | MEN1 (0.62) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10691913 | 0.81 | CYP2C9 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4085333 | 0.80 | CA12 (0.80) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL11280924 | 0.80 | CA12 (0.59) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL4768191 | 0.79 | GAA (0.49) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL1082403 | 0.79 | CA12 (0.77) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL3704958 | 0.79 | CA12 (0.71) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL4770148 | 0.78 | GAA (0.47) | CA12CA1CA2CA9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | CA12 4578/4885CA1 3010/4885CA2 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.